30182-26-4

Basic information

• Product Name: 6-chloro-N⁴-cyclohexylpyrimidine-2,4-diamine
• Synonyms: 6-chloro-N⁴-cyclohexylpyrimidine-2,4-diamine
• CAS NO: 30182-26-4
• Molecular Weight: 226.709
• Mol File: 30182-26-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6-chloro-N⁴-cyclohexylpyrimidine-2,4-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-N⁴-cyclohexylpyrimidine-2,4-diamine(30182-26-4)
• EPA Substance Registry System: 6-chloro-N⁴-cyclohexylpyrimidine-2,4-diamine(30182-26-4)

Safety Data

• Hazardous Substances Data: 30182-26-4(Hazardous Substances Data)

Usage

Usage

Used in the synthesis of pharmaceutical drugs
Potential applications in medicinal chemistry
Biological activities
Reagent in chemical reactions

Safety Precautions

Handle and store with proper safety precautions due to potential hazards if mishandled.

Upstream product

• 56-05-3 2-Amino-4,6-dichloropyrimidine 
• 108-91-8 cyclohexylamine 

Relevant articles and documents

Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation

We describe the discovery of three structurally differentiated potent and selective MTH1 inhibitors and their subsequent use to investigate MTH1 as an oncology target, culminating in target (in)validation. Tetrahydronaphthyridine 5 was rapidly identified as a highly potent MTH1 inhibitor (IC50 = 0.043 nM). Cocrystallization of 5 with MTH1 revealed the ligand in a φ-cis-N-(pyridin-2-yl)acetamide conformation enabling a key intramolecular hydrogen bond and polar interactions with residues Gly34 and Asp120. Modification of literature compound TH287 with O- and N-linked aryl and alkyl aryl substituents led to the discovery of potent pyrimidine-2,4,6-triamine 25 (IC50 = 0.49 nM). Triazolopyridine 32 emerged as a highly selective lead compound with a suitable in vitro profile and desirable pharmacokinetic properties in rat. Elucidation of the DNA damage response, cell viability, and intracellular concentrations of oxo-NTPs (oxidized nucleoside triphosphates) as a function of MTH1 knockdown and/or small molecule inhibition was studied. Based on our findings, we were unable to provide evidence to further pursue MTH1 as an oncology target.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.